Overview
Biopharmaceutical firm recorded collaboration revenue in Q2 vs nothing last year
Company's Q2 operating expenses increased due to obesity program costs
Company completed $18.2 mln public offering, strengthening balance sheet
Outlook
Palatin plans IND submission for oral MC4R agonist PL7737 in first half of 2026
Company targets second half of 2026 for peptide MC4R agonist clinical trials
Palatin focuses on hypothalamic obesity and Prader-Willi syndrome in clinical studies
Result Drivers
OBESITY PROGRAM ADVANCEMENTS - Palatin's MC4R-based obesity programs, including PL7737 and next-gen peptide agonists, are progressing toward clinical trials, focusing on hypothalamic obesity and Prader-Willi syndrome
SUBLICENSING AGREEMENT - Sublicensing of MC1R agonist PL9643 provided $3.8 mln upfront and potential future payments, enhancing focus on obesity portfolio
PUBLIC OFFERING - Completed $18.2 mln public offering, restoring NYSE American listing compliance and strengthening balance sheet
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 EPS | -$2.86 |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Palatin Technologies Inc is $53.00, about 204.8% above its February 13 closing price of $17.39
Press Release: ID:nPn4m3f6Ma
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)